Baillie Gifford & Company Lowered Td Ameritrade Holding (AMTD) Stake By $830,893; Inflarx N.V. (IFRX) Shorts Increased By 31.95%

TD Ameritrade Holding Corporation (NASDAQ:AMTD) Logo

Baillie Gifford & Company decreased Td Ameritrade Holding Corp (AMTD) stake by 0.22% reported in 2019Q2 SEC filing. Baillie Gifford & Company sold 16,957 shares as Td Ameritrade Holding Corp (AMTD)’s stock declined 2.80%. The Baillie Gifford & Company holds 7.67M shares with $382.89 million value, down from 7.69 million last quarter. Td Ameritrade Holding Corp now has $18.80B valuation. The stock increased 1.50% or $0.51 during the last trading session, reaching $34.28. About 4.77M shares traded or 20.78% up from the average. TD Ameritrade Holding Corporation (NYSE:AMTD) has declined 12.14% since October 10, 2018 and is downtrending. It has underperformed by 12.14% the S&P500. Some Historical AMTD News: 26/03/2018 – Interactive, Fidelity TD Ameritrade Top Best Online Brokers — Barrons.com; 25/05/2018 – Toronto-Dominion CEO Says `Uncertainty’ Canada’s Biggest Risk; 16/05/2018 – TD Ameritrade Institutional Expands RIA Access to Environmental, Social and Governance Investing; 15/05/2018 – MILLENNIUM EXITED EQIX, AMTD, COO, PUMP, KS IN 1Q: 13F; 26/03/2018 – It also said clients can still access their accounts through TD’s Thinkorswim platform or the Mobile Trader application; 21/03/2018 – Old Mutual Voyager Global Dynamic Adds TD Ameritrade; 30/05/2018 – TD Ameritrade Announces Personalized Portfolios; 26/03/2018 – TD Ameritrade clients are unable to access their accounts following a system-wide outage; 16/05/2018 – TD Ameritrade Launches ‘Instant’ ESG Portfolios for RIAs — Barrons.com; 25/04/2018 – TD Ameritrade Closes Below 50-Day Moving Average: Technicals

Inflarx N.V. (NASDAQ:IFRX) had an increase of 31.95% in short interest. IFRX’s SI was 1.24M shares in October as released by FINRA. Its up 31.95% from 941,700 shares previously. With 1.56M avg volume, 1 days are for Inflarx N.V. (NASDAQ:IFRX)’s short sellers to cover IFRX’s short positions. The SI to Inflarx N.V.’s float is 8.17%. The stock decreased 0.44% or $0.01 during the last trading session, reaching $2.28. About 90,530 shares traded. InflaRx N.V. (NASDAQ:IFRX) has declined 90.11% since October 10, 2018 and is downtrending. It has underperformed by 90.11% the S&P500. Some Historical IFRX News: 29/03/2018 – lnflaRx Full Year 2017 Financial & Operating Results; 17/05/2018 – InflaRx 1Q Loss/Shr EUR0.04; 08/03/2018 InflaRx announces first patient enrolled in Phase IIb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 17/05/2018 – INFLARX NV – CASH POSITION APPROXIMATELY US$137 MLN (EUR 115 MLN) AS OF MARCH 31, 2018; 29/03/2018 – InflaRx Full Year 2017 Financial & Operating Results; 08/05/2018 – INFLARX N.V. REPORTS CLOSING OF PRIMARY, SECONDARY OFFERING; 08/05/2018 – InflaRx N.V. Announces Closing of Primary and Secondary Offering of Common Shrs; 08/03/2018 – lnflaRx announces first patient enrolled in Phase llb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 17/05/2018 – InflaRx 1Q Loss EUR10.3M; 03/05/2018 – INFLARX PRIMARY, SECONDARY OFFERINGS PRICES AT $34.00 PER SHARE

More notable recent InflaRx N.V. (NASDAQ:IFRX) news were published by: Finance.Yahoo.com which released: “Do Insiders Own Shares In InflaRx N.V. (NASDAQ:IFRX)? – Yahoo Finance” on July 19, 2019, also Benzinga.com with their article: “Stocks That Hit 52-Week Lows On Tuesday – Benzinga” published on October 08, 2019, Finance.Yahoo.com published: “Hedge Funds Have Never Been This Bullish On InflaRx N.V. (IFRX) – Yahoo Finance” on June 29, 2019. More interesting news about InflaRx N.V. (NASDAQ:IFRX) were released by: Finance.Yahoo.com and their article: “The Daily Biotech Pulse: Safety Scare For Anaptys’ Psoriasis Drug, NewLink Genetics To Merge With Lumos, Insider Buy Props Up VBI Vaccines – Yahoo Finance” published on October 01, 2019 as well as Globenewswire.com‘s news article titled: “InflaRx Reports Second Quarter 2019 Financial & Operating Results – GlobeNewswire” with publication date: August 14, 2019.

InflaRx GmbH, a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States. The company has market cap of $59.20 million. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. It currently has negative earnings. The firm is involved developing IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and other chronic/autoimmune diseases, as well as IFX-2 for the treatment of chronic inflammation and autoimmune diseases.

Baillie Gifford & Company increased Watsco Inc (NYSE:WSO) stake by 329,126 shares to 1.46M valued at $238.21 million in 2019Q2. It also upped Abiomed (NASDAQ:ABMD) stake by 1.14 million shares and now owns 2.22M shares. Banco Bradesco Pn Adr (NYSE:BBD) was raised too.

More notable recent TD Ameritrade Holding Corporation (NASDAQ:AMTD) news were published by: Seekingalpha.com which released: “TD Ameritrade In A $0 Commission World – Seeking Alpha” on October 08, 2019, also Fool.com with their article: “Why TD Ameritrade, Bausch Health, and Aurora Cannabis Slumped Today – The Motley Fool” published on October 01, 2019, Fool.com published: “Trading Fees Are So Yesterday – Motley Fool” on October 10, 2019. More interesting news about TD Ameritrade Holding Corporation (NASDAQ:AMTD) were released by: Benzinga.com and their article: “UBS Upgrades E-Trade, Downgrades TD Ameritrade After Commission-Free Shake-Up – Benzinga” published on October 07, 2019 as well as Benzinga.com‘s news article titled: “TD Ameritrade Joins The Party, Cuts Commissions On Stocks, ETFs And Options – Benzinga” with publication date: October 01, 2019.

Among 8 analysts covering TD Ameritrade Holding (NYSE:AMTD), 2 have Buy rating, 2 Sell and 4 Hold. Therefore 25% are positive. TD Ameritrade Holding has $62 highest and $3000 lowest target. $43.88’s average target is 28.00% above currents $34.28 stock price. TD Ameritrade Holding had 18 analyst reports since April 11, 2019 according to SRatingsIntel. Barclays Capital maintained it with “Overweight” rating and $62 target in Thursday, April 11 report. The stock of TD Ameritrade Holding Corporation (NASDAQ:AMTD) earned “Hold” rating by Deutsche Bank on Wednesday, October 2. Barclays Capital maintained TD Ameritrade Holding Corporation (NASDAQ:AMTD) on Tuesday, July 23 with “Overweight” rating. The stock of TD Ameritrade Holding Corporation (NASDAQ:AMTD) earned “Underweight” rating by Barclays Capital on Wednesday, October 2. Credit Suisse maintained it with “Neutral” rating and $6100 target in Tuesday, July 23 report. The rating was downgraded by Deutsche Bank to “Hold” on Friday, August 9. The rating was maintained by Citigroup with “Neutral” on Thursday, September 19. As per Wednesday, July 24, the company rating was maintained by Morgan Stanley. The firm has “Buy” rating given on Monday, June 24 by UBS. Wells Fargo downgraded it to “Underperform” rating and $3000 target in Thursday, October 3 report.

Analysts await TD Ameritrade Holding Corporation (NASDAQ:AMTD) to report earnings on October, 28. They expect $0.93 earnings per share, up 1.09% or $0.01 from last year’s $0.92 per share. AMTD’s profit will be $510.06 million for 9.22 P/E if the $0.93 EPS becomes a reality. After $1.04 actual earnings per share reported by TD Ameritrade Holding Corporation for the previous quarter, Wall Street now forecasts -10.58% negative EPS growth.

TD Ameritrade Holding Corporation (NASDAQ:AMTD) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *